Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Apr 14, 2023; 29(14): 2188-2201
Published online Apr 14, 2023. doi: 10.3748/wjg.v29.i14.2188
Table 1 Baseline demographic features of the cohort

HBV (n = 1064)
HCV (n = 507)
NBNC (n = 391)
P value
Missing rate
Demographics
Age (yr)52.05 ± 10.9058.69 ± 10.8451.97 ± 13.10< 0.0001 (2 & 3, 1 & 2)0.00%
Male sex, n (%)825 (77.5)273 (53.8)233 (59.6)< 0.00010.00%
Weight (kg)68.36 ± 12.3064.53 ± 12.1770.94 ± 14.09< 0.0001 (2 & 3, 1 & 2, 1 & 3)0.97%
Height (cm)166.34 ± 7.62161.67 ± 8.57164.18 ± 8.75< 0.0001 (2 & 3, 1 & 2, 1 & 3)2.80%
BMI (kg/m2)24.66 ± 3.6224.58 ± 3.7526.25 ± 4.23< 0.0001 (2 & 3, 1 & 3)3.47%
Lab data at ARFI study
Spleen index (cm2)31.97 ± 14.4733.63 ± 16.7234.07 ± 16.050.0640 (1 & 3)0.03%
Albumin (mg/dL)4.345 ± 0.514.29 ± 0.514.43 ± 0.480.0040 (2 & 3)42.15%
AST (U/L)57.50 ± 102.1662.46 ± 58.0858.40 ± 50.721.12%
ALT (U/L)75.05 ± 162.8871.52 ± 69.6183.46 ± 78.321.33%
Bilirubin (mg/dL)0.93 ± 1.230.91 ± 1.190.92 ± 1.2112.79%
Prothrombin time (INR)1.10 ± 0.131.11 ± 0.211.06 ± 0.130.0040 (2 & 3, 1 & 3)42.15%
Platelets (109/L)177.86 ± 61.86170.13 ± 60.19218.96 ± 76.08< 0.0001 (2 & 3, 1 & 3)13.25%
FIB42.454 ± 2.7203.31 ± 3.042.06 ± 2.13< 0.0001 (2 & 3, 1 & 2)23.35%
Mean ARFI (m/s)11.40 ± 0.461.60 ± 0.611.42 ± 0.62< 0.0001 (2 & 3, 1 & 2)0.00%
Stiffness status1< 0.0001
Cirrhosis331 (31.1)163 (32.1)78 (19.9)
Severe fibrosis138 (13.0)110 (21.7)61 (15.6)
Moderate fibrosis114 (10.7)68 (13.4)29 (7.4)
Mild or non-fibrosis481(45.2)166(32.7)223(57.0)
Comorbidities
Hypertension181 (17.0)147 (29.0)115 (29.4)< 0.0001
Diabetes119 (11.2)103 (20.3)76 (19.4)< 0.0001
Heart failure14 (1.3)17 (3.4)7 (1.8)0.023
Atrial fibrillation9 (0.8)11 (2.2)5 (1.3)0.091
Myocardial infraction12 (1.1) 5 (1.0)2 (0.5)0.567
Ischemic stroke6 (0.6)17 (3.4)8 (2.0)< 0.0001
Dyslipidemia170 (16.0)95 (18.7)125 (32.0)< 0.0001
Follow-up (year)
mean ± SD4.59 ± 2.224.34 ± 2.353.13 ± 2.15< 0.0001 (1 & 3, 2 & 3)
Median/IQR4.54/3.593.97/3.882.61/3.23